Maxim analyst Jason McCarthy upgraded Coherus Biosciences (CHRS) to Buy from Hold.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Oncology’s Earnings Call Highlights Growth and Challenges
- Coherus Biosciences: Buy Rating Affirmed Amid Strong Sales Alignment and Promising Pipeline Developments
- Coherus Biosciences: Promising Growth and Strategic Positioning Justify Buy Rating
- Coherus Oncology Reports Strong Q2 2025 Growth
- Coherus Biosciences reports Q2 EPS (39c), consensus (27c)